Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Efficacy was evaluated in a single-arm cohort of PLEIADES study
02 Dec 2021
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Efficacy was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label study. This cohort enrolled 66 patients with relapsed or refractory multiple myeloma who received at least one prior line of therapy. Patients received Darzalex Faspro 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously in combination with Kyprolis (20/70 mg/m2 once weekly regimen) and dexamethasone.

The main efficacy outcome measure was overall response rate (ORR). The ORR was 84.8% (95% confidence interval [CI] 73.9%, 92.5%). At a median follow-up of 9.2 months, the median duration of response had not been reached and an estimated 85.2% (95% CI 72.5, 92.3) maintained response for at least 6 months and 82.5% (95% CI 68.9, 90.6) maintained response for at least 9 months.

The most common adverse reactions (≥20%) occurring in patients treated with Darzalex Faspro, Kyprolis, and dexamethasone were upper respiratory tract infections, fatigue, insomnia, hypertension, diarrhoea, cough, dyspnoea, headache, pyrexia, nausea, and peripheral oedema.

The recommended Darzalex Faspro dose is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24, and once every 4 weeks starting week 25 until disease progression or unacceptable toxicity.

The recommended dosage regimens of Kyprolis when administered in combination with Darzalex Faspro are the following: 

  • Once weekly 20/70 mg/m2 regimen: Kyprolis 20 mg/m2 administered by i.v. infusion over 30 minutes on cycle 1 day 1 and if a dose of 20 mg/m2 is tolerated, 70 mg/m2 as a 30-minute i.v. infusion on cycle 1, day 8 and day 15, and then day 1, 8, and 15 of each 28-day cycle.
  • Twice weekly 20/56 mg/m2 regimen: Kyprolis 20 mg/m2 administered by i.v. infusion over 30 minutes on cycle 1 day 1 and day 2 and, if a dose of 20 mg/m2 is tolerated, 56 mg/m2 administered by i.v. infusion over 30 minutes on cycle 1, day 8, 9, 15, and 16, and then on day 1, 2, 8, 9, 15, 16 of each 28-day cycle

Full prescribing information for Darzalex Faspro is available here, and for Kyprolis here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.